Prognostic and Immune Infiltration Analysis of Transaldolase 1 (TALDO1) in Hepatocellular Carcinoma

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• European Assoc Study L. EASL clinical practice guidelines: management of Hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0
   PubMed Web of Science ®Google Scholar
• Liu C-L, Hsu Y-C, Lee -J-J, et al. Targeting the pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells. Mol Cell Endocrinol. 2020;2020:499.
   Google Scholar
• Li Q, Qin T, Bi Z, et al. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat Commun. 2020;11(1):1.
   PubMed Web of Science ®Google Scholar
• Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein Cell. 2014;5(8):592–602. doi:10.1007/s13238-014-0082-8
   PubMed Web of Science ®Google Scholar
• Grammatikopoulos T, Hadzic N, Foskett P, et al. Liver disease and risk of Hepatocellular carcinoma in children with mutations in TALDO1. Hepatol Commun. 2022;6(3):473–479. doi:10.1002/hep4.1824
   PubMed Web of Science ®Google Scholar
• Wu Y-R, Lee Y-C, W-M L, et al. High transaldolase 1 expression predicts poor survival of patients with upper tract urothelial carcinoma. Pathol Int. 2021;71(7):463–470. doi:10.1111/pin.13101
   PubMed Web of Science ®Google Scholar
• Leduc CA, Crouch EE, Wilson A, et al. Novel association of early onset hepatocellular carcinoma with transaldolase deficiency. JIMD Rep. 2014;12:121–127.
   PubMedGoogle Scholar
• Basta PV, Bensen JT, Tse C-K, et al. Genetic variation in transaldolase 1 and risk of squamous cell carcinoma of the head and neck. Cancer Detect Prev. 2008;32(3):200–208. doi:10.1016/j.cdp.2008.08.008
   PubMedGoogle Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2022. doi:10.1002/hep.32740
   Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Fontana R, Mestre-Farrera A, Yang J, et al. Update on epithelial-mesenchymal plasticity in cancer progression. Mech Dis. 2023;19:1.
   Google Scholar
• Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402–418. doi:10.1016/j.apsb.2015.07.005
   PubMed Web of Science ®Google Scholar
• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Risha Y, Susevski V, Huttmann N, et al. Breast cancer-derived microvesicles are the source of functional metabolic enzymes as potential targets for cancer therapy. Biomedicines. 2021;9(2):107. doi:10.3390/biomedicines9020107
   PubMed Web of Science ®Google Scholar
• Verhoeven NM, Huck JHJ, Roos B, et al. Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway. Am J Hum Genet. 2001;68(5):1086–1092. doi:10.1086/320108
   PubMed Web of Science ®Google Scholar
• Hanczko R, Fernandez DR, Doherty E, et al. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest. 2009;119(6):1546–1557. doi:10.1172/JCI35722
   PubMed Web of Science ®Google Scholar
• Suzuki S, Asamoto M, Tsujimura K, Shirai T. Specific differences in gene expression profile revealed by cDNA microarray analysis of glutathione S-transferase placental form (GST-P) immunohistochemically positive rat liver foci and surrounding tissue. Carcinogenesis. 2004;25(3):439–443. doi:10.1093/carcin/bgh030
   PubMed Web of Science ®Google Scholar
• Wang C, Guo K, Gao D, et al. Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples. Cancer Lett. 2011;313(2):154–166. doi:10.1016/j.canlet.2011.08.031
   PubMed Web of Science ®Google Scholar
• Ding Y, Gong C, Huang D, et al. Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. Nat Commun. 2018;9. doi:10.1038/s41467-018-06651-x
   Web of Science ®Google Scholar
• Alfarsi LH, El Ansari R, Craze ML, et al. SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2021;189(2):317–331. doi:10.1007/s10549-021-06298-1
   PubMed Web of Science ®Google Scholar
• Colombo E, Banki K, Tatum AH, et al. Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J Clin Invest. 1997;99(6):1238–1250. doi:10.1172/JCI119281
   PubMed Web of Science ®Google Scholar
• Al-Mayouf SM, AlTassan RS, AlOwain MA. Systemic lupus erythematosus in a girl with PTEN variant and transaldolase deficiency: a novel phenotype. Clin Rheumatol. 2020;39(11):3511–3515. doi:10.1007/s10067-020-05205-1
   PubMed Web of Science ®Google Scholar